[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-355070-105":59,"doc-detail-355070-en":131},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":124,"head_meta":126,"extra_data":128,"updated_unix":130},105,"en","recent-advances-in-molecular-classification-and-multimodal-treatment-of-intrahepatic-cholangiocarcinoma","Recent advances in molecular classification and multimodal treatment of intrahepatic cholangiocarcinoma","","Intrahepatic cholangiocarcinoma (ICC) is the second most common primary liver malignancy, marked by aggressive biology and poor prognosis. Surgical resection is potentially curative, yet most patients are not eligible at diagnosis and recurrence remains frequent even after R0 resection. Locoregional options, including transarterial chemoembolization, hepatic arterial infusion chemotherapy, and radiotherapy, are increasingly integrated with surgery and systemic therapy.",{"@graph":69,"@context":123},[70,84,106],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/recent-advances-in-molecular-classification-and-multimodal-treatment-of-intrahepatic-cholangiocarcinoma/355070/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/recent-advances-in-molecular-classification-and-multimodal-treatment-of-intrahepatic-cholangiocarcinoma/355070.png","ImageObject",300,407,{"name":92,"@type":93},"Noah","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-19","2026-09-22",true,{"@type":102,"interactionType":103,"userInteractionCount":105},"InteractionCounter",{"@type":104},"ViewAction",12,{"@type":107,"mainEntity":108},"FAQPage",[109,115,119],{"name":110,"@type":111,"acceptedAnswer":112},"Why is intrahepatic cholangiocarcinoma (ICC) difficult to treat?","Question",{"text":113,"@type":114},"ICC has aggressive biological behavior and poor prognosis. Most patients are ineligible for surgery at diagnosis, and recurrence remains high even after curative resection.","Answer",{"name":116,"@type":111,"acceptedAnswer":117},"What treatment approaches are included in modern multimodal care for ICC?",{"text":118,"@type":114},"Multimodal strategies combine surgery with locoregional therapies such as transarterial chemoembolization, hepatic arterial infusion chemotherapy, and radiotherapy, along with systemic therapy including targeted therapy and immunotherapy.",{"name":120,"@type":111,"acceptedAnswer":121},"How does molecular classification affect treatment selection in ICC?",{"text":122,"@type":114},"Genomic sequencing and tumor microenvironment research enable molecular classification that guides selection of targeted and immune-based therapies. Molecular profiling can also influence patient selection for resection and transplantation within multimodal pathways.","https://schema.org",{"og:url":83,"og:type":125,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":127,"canonical":83},"index,follow",{"doc_id":129,"site_id":62},355070,1790831296,{"code":4,"msg":5,"data":132},{"doc_id":129,"user_id":133,"nickname":92,"user_avatar":134,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":135,"file_id":136,"file_url":137,"file_type":138,"file_size":139,"view_count":105,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":140,"language":141,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":142,"faqs":143,"seo_title":144,"seo_description":67,"update_tm":145,"read_time":36,"preview_page_count":19,"preview_urls":146},8796095462418,"https://ap-avatar.wpscdn.com/avatar/80000253c1241d02b47?x-image-process=image/resize,m_fixed,w_180,h_180&k=1778826106357471780","Saboor and Lu World Journal of Surgical Oncology (2026) 24:76  \n[https://doi.org/10.1186/s12957-025-04188-0](https://doi.org/10.1186/s12957-025-04188-0)  \nWorld Journal of Surgical Oncology  \nREVIEW Open Access  \nRecent advances in molecular classification and multimodal treatment of intrahepatic cholangiocarcinoma  \nFazal Saboor1,2 and Jiong Lu 1,2*  \nAbstract  \nIntrahepatic cholangiocarcinoma (ICC) is the second most common primary liver malignancy and is characterized by aggressive biological behavior and poor prognosis. Surgical resection remains the only potentially curative treatment; however, most patients are ineligible for surgery at diagnosis, and recurrence rates remain high even after curative resection.  \nIn recent years, locoregional therapies including transarterial chemoembolization, hepatic arterial infusion chemotherapy, and radiotherapy have achieved promising clinical outcomes and are increasingly incorporated into multimodal treatment strategies alongside surgery and systemic therapy. Liver transplantation has also shown potential benefits in carefully selected early-stage cases. Meanwhile, advances in targeted therapy and immunotherapy—including phase III trials of gemcitabine–cisplatin combined with PD-1/PD-L1 inhibitors—have further supported the development of personalized, multidisciplinary treatment strategies in advanced disease.  \nThe rapid development of genomic sequencing and tumor microenvironment research has enabled molecular classification of ICC, providing valuable guidance for the selection of targeted and immune-based therapies. Importantly, molecular profiling is now also influencing patient selection for resection and transplantation within multimodal treatment pathways, and recent data support fluoropyrimidine-based adjuvant therapy and emerging perioperative chemotherapy strategies in resectable biliary tract cancers. Nevertheless, certain treatment strategies, particularly in the context of multimodal integration, require further validation through large-scale prospective clinical studies.  \nThis review summarizes recent progress in molecular classification, local and systemic therapeutic approaches, and highlights how molecular profiling and biomarker-guided strategies contribute to personalized, precision, and multimodal treatment of intrahepatic cholangiocarcinoma.  \nKeywords Intrahepatic Cholangiocarcinoma (ICC), Molecular classification, Surgical treatment, Systemic therapy, Locoregional therapy, Multimodal therapy  \n*Correspondence: Jiong Lu[lujiong@scu.edu.cn](lujiong@scu.edu.cn)  \n1Division of Biliary Surgery, Department of General Surgery, West China Hospital, Sichuan University, Chengdu 610041, Sichuan, China 2Research Center for Biliary Diseases, West China Hospital, Sichuan University, Chengdu 610041, Sichuan, China  \n© The Author(s) 2026. Open Access This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if you modified the licensed material. You do not have permission under this licence to share adapted material derived from this article or parts of it. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit [http://creati](http://creati)[vecommons.org/licenses/by-nc-nd/4.0/](vecommons.org/licenses/by-nc-nd/4.0/.)[.](vecommons.org/licenses/by-nc-nd/4.0/.)  \nSaboor and Lu World Journal of ","cbCairKrPQ9gJVeL","https://ap.wps.com/l/cbCairKrPQ9gJVeL","pdf",2298708,16,"English","# Abstract\n# Introduction\n## Risk factors and disease progression\n## Molecular classification and therapeutic implications\n## Current surgical and emerging treatment strategies","[{\"question\":\"Why is intrahepatic cholangiocarcinoma (ICC) difficult to treat?\",\"answer\":\"ICC has aggressive biological behavior and poor prognosis. Most patients are ineligible for surgery at diagnosis, and recurrence remains high even after curative resection.\"},{\"question\":\"What treatment approaches are included in modern multimodal care for ICC?\",\"answer\":\"Multimodal strategies combine surgery with locoregional therapies such as transarterial chemoembolization, hepatic arterial infusion chemotherapy, and radiotherapy, along with systemic therapy including targeted therapy and immunotherapy.\"},{\"question\":\"How does molecular classification affect treatment selection in ICC?\",\"answer\":\"Genomic sequencing and tumor microenvironment research enable molecular classification that guides selection of targeted and immune-based therapies. Molecular profiling can also influence patient selection for resection and transplantation within multimodal pathways.\"}]","Recent advances in molecular classification and multimodal treatment of intrahepatic cholangiocarcinoma | PDF",1790115722,[147,151,155,159],{"page_no":8,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/bdd1c0210854b8ef122a93e351f27658.webp",983,1310,{"page_no":14,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/b58ba634b164005bc6308c341af6bc21.webp",982,1309,{"page_no":81,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/7ec664cdfc2e5c2d3a623ee1f2835d9c.webp",981,1308,{"page_no":19,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/be74471e7f779bc7026636d414b1ea7c.webp",980,1306]